In the first quarter, Boston Scientific (BSX) witnessed a strong worldwide launch for its RESONATE family of high-voltage devices, including its cardiac resynchronization therapy defibrillator (or CRT-D) and implantable cardioverter defibrillator (or ICD) systems. These devices are fitted with EnduraLife, the longest-life battery technology in the world.
According to the National Institute for Health and Care Excellence (or NICE), EnduraLife-powered CRT-Ds help reduce the number of replacement procedures that patients undergo and thereby result in higher savings for the healthcare system.
The RESONATE family of devices is capable of providing personalized therapy to patients due to the SmartCRT technology of MultiSite Pacing and the HeartLogic Suite algorithm for better management of heart failure. Additionally, the company has provided the capability to make RESONATE devices MRI-compliant.
The above diagram highlights the key characteristics of the RESONATE family of devices and the research pipeline for the HeartLogic Heart Failure Diagnostic Service.
HeartLogic diagnostic algorithm
HeartLogic, the only FDA-approved implantable heart failure diagnostic service, has demonstrated a sensitivity of almost 70% in predicting heart failure with a median notice period of 34 days prior to the event. This implies that a physician can manage the issue if it’s reversible. This algorithm is also expected to reduce physicians’ workloads, as they otherwise have to monitor all patients—not just high-risk ones—in the absence of such an alert.
Boston Scientific has designed a broad clinical program for evaluating the benefits of the HeartLogic algorithm. The company is also engaging with various healthcare systems across the world to increase the adoption of this diagnostic algorithm.
To further boost uptake of its subcutaneous implantable defibrillator (or S-ICD) devices, Boston Scientific has launched the Emblem MRI S-ICD system to enable implanted patients to undergo MRIs safely. The company has also introduced an automatic screening tool to identify patients eligible for the S-ICD implant.
Boston Scientific also prefers to opt for the two-incision technique when implanting S-ICD systems. This implant procedure is expected to reduce procedure time as well as result in better post-operative cosmetic outcomes for patients. The company has also added the SmartPass algorithm to its EMBLEM S-ICD system to reduce the rate of inappropriate shocks in the transvenous system.
In the next article, we’ll discuss future growth opportunities for Boston Scientific’s cardiac rhythm management portfolio in greater detail.